PLIVA, Inc. v. Mensing
The Supreme Court ruled that federal law blocks state lawsuits against generic drug manufacturers for failing to add stronger warnings, because federal rules require generic labels to always match the brand-name label and generic makers cannot change that label on their own.
The decision means people harmed by a generic drug's inadequate warning generally cannot sue, even though people who took the identical brand-name drug can, creating a sharp legal divide based on which version of a drug a pharmacist happened to dispense.
“The question for “impossibility” is whether the private party could independently do under federal law what state law requires of it.”
The majority's core test for deciding when state and federal law conflict.
How it got here: Federal trial courts allowed the suits to proceed; the Fifth and Eighth Circuits both rejected the manufacturers' preemption defense, and the manufacturers asked the Supreme Court to review both consolidated cases.
The Case in Depth
What happened
Gladys Mensing and Julie Demahy were prescribed the drug Reglan but received generic metoclopramide from their pharmacists. After using it for years as prescribed, both developed tardive dyskinesia, a severe and often irreversible movement disorder linked to long-term use. They sued the generic manufacturers under Minnesota and Louisiana tort law, claiming the companies knew the warning labels understated the drug's risks and failed to strengthen them.
The question before the Court
If federal rules require generic drug labels to always match the brand-name label, can people who took the generic version still sue the generic maker for not adding a stronger safety warning?
The Court's answer
Yes — the Court ruled that federal law preempts these state failure-to-warn claims against generic drug manufacturers. Because federal regulations require a generic drug's label to always match its brand-name counterpart, and generic manufacturers cannot change that label on their own initiative, it was legally impossible for them to comply with a state-law duty demanding a stronger warning.
The Court rejected the argument that the manufacturers should have to show they tried and failed to get the FDA to help change the label before claiming preemption. It held that the relevant question is only whether a company could act independently under existing federal law — not whether some future agency or third-party action might eventually make compliance possible. Because the only step the manufacturers could take alone was asking the FDA for help, which state law did not require, their state-law duty to warn conflicted with federal law and was preempted.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Roughly three-quarters of prescriptions filled in the U.S. are generic. Under this ruling, patients hurt by inadequate warnings on generic drugs generally lose their right to sue the manufacturer, while patients taking the identical brand-name drug keep that right — turning access to compensation on the accident of which version a pharmacy dispensed.
What changes now
The Fifth and Eighth Circuit judgments are reversed and the cases sent back for further proceedings consistent with the ruling, which effectively means the plaintiffs' failure-to-warn claims cannot proceed. The decision is a final merits ruling, not a temporary order. It leaves in place a lasting split in whether injured patients can sue over inadequate drug warnings depending on whether they took a brand-name or generic drug, a gap the opinion notes only Congress or the FDA can close by changing the law or regulations.
What this does not decide
The Court expressly did not decide whether federal and state law "directly conflict" in situations beyond strict impossibility, such as obstacle preemption, and did not resolve whether generic manufacturers truly have a duty to request FDA label changes — it simply assumed that duty existed for purposes of deciding this case.
Concurrences and dissents
Concurrence in part — Justice Kennedy
Justice Kennedy joined the Court's opinion in full except for Part III-B-2, the section laying out the theory that the Supremacy Clause functions as a historical 'non obstante' provision instructing courts not to strain to reconcile conflicting state and federal law. He agreed with the outcome and the impossibility analysis but did not sign onto that broader historical argument about the Supremacy Clause's origins.
Dissent — Justice Sotomayor
“In other words, the mere possibility of impossibility is not enough.”The dissent's summary of the traditional, more demanding standard for proving preemption.
Justice Sotomayor argued the majority diluted the demanding impossibility-preemption standard, which traditionally required proof of an 'inevitable collision' between state and federal law, not merely a hypothetical one. Because the manufacturers never even asked the FDA to strengthen the label, she would have held they failed to prove impossibility. She warned the ruling arbitrarily strips most drug consumers of a remedy based on the pharmacist's choice of brand versus generic, undermines Wyeth v. Levine, and rests on an unsupported new theory of the Supremacy Clause.
How the Court got there
The legal reasoning, step by step
- The Court first established what federal law actually required: generic drug manufacturers have an ongoing duty of 'sameness,' meaning their warning label must always match the approved brand-name label, unlike brand-name makers who bear direct responsibility for their own label's content.
- Deferring to the FDA's own interpretation of its regulations, the Court found that generic manufacturers could not unilaterally strengthen their labels through the agency's expedited 'changes-being-effected' process, nor could they send extra warning letters to doctors, because either move would make their label inconsistent with the brand-name label.
- Applying the doctrine of impossibility preemption — which asks whether a private party can independently satisfy a state-law duty without violating federal law — the Court held that a state law is preempted whenever it is impossible for a company to comply with both state and federal duties at once.
- The Court reasoned that even though the manufacturers might have asked the FDA to help persuade the brand-name maker to change the label, that possibility didn't matter, because the relevant test is only whether the company could act on its own under existing federal law, not whether a third party or agency might eventually make compliance possible.
- Because federal law barred the manufacturers from independently changing their labels, and the only action they could take on their own — asking the FDA for help — was not what state law required of them, the Court concluded that the state failure-to-warn claims directly conflicted with, and were therefore preempted by, federal law.
Doctrinal impact
Cases affected by this decision
Distinguishes Wyeth v. Levine (555 U.S. 555)
Held not to control because brand-name makers, unlike generic makers, could unilaterally strengthen their own labels.